Prokidney (PROK) Consolidated Net Income (2021 - 2026)
Prokidney (PROK) posted quarterly Consolidated Net Income of -$42.6 million for Q1 2026, down 12.3% year-over-year from -$48.6 million in Q1 2025, and down 390.69% quarter-over-quarter from -$8.7 million in Q4 2025.
Prokidney (PROK) Consolidated Net Income (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Consolidated Net Income for 6 consecutive years, with -$42.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 12.3% year-over-year to -$42.6 million; the TTM figure through Mar 2026 stood at -$124.1 million (up 25.21% YoY), while the FY2025 annual figure was -$119.4 million, up 26.87% from the prior year.
- Consolidated Net Income eased to -$42.6 million in Q1 2026 per PROK's latest filing, from -$8.7 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$8.7 million in Q4 2025 and bottomed at -$67.5 million in Q1 2022.
- Historically, Consolidated Net Income has averaged -$35.8 million across 5 years, with a median of -$36.9 million in 2023.
- Annual changes were most pronounced in 2022 — Consolidated Net Income tumbled 1302215.71% — and 2025, when it surged 82.08%.
- Prokidney's Consolidated Net Income stood at -$24.6 million in 2022, then advanced by 11.59% to -$21.7 million in 2023, then slumped by 123.18% to -$48.5 million in 2024, then soared by 82.08% to -$8.7 million in 2025, then slumped by 390.69% to -$42.6 million in 2026.
- Business Quant data shows PROK's Consolidated Net Income at -$42.6 million in Q1 2026, -$8.7 million in Q4 2025, and -$35.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Prokidney | 679.95 Mn | 679.95 Mn | - | -46.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.44 Mn |
| Mar 31, 2026 | -42.62 Mn |
| Dec 31, 2025 | -8.69 Mn |
| Sep 30, 2025 | -35.84 Mn |
| Jun 30, 2025 | -36.97 Mn |
| Mar 31, 2025 | -37.95 Mn |
| Dec 31, 2024 | -48.48 Mn |
| Sep 30, 2024 | -41.05 Mn |
| Jun 30, 2024 | -38.47 Mn |
| Mar 31, 2024 | -35.33 Mn |
| Dec 31, 2023 | -21.72 Mn |
| Sep 30, 2023 | -41.99 Mn |
| Jun 30, 2023 | -34.82 Mn |
| Mar 31, 2023 | -36.91 Mn |
| Dec 31, 2022 | -24.57 Mn |
| Sep 30, 2022 | -33.95 Mn |
| Jun 30, 2022 | -22.13 Mn |
| Mar 31, 2022 | -67.49 Mn |
| Dec 31, 2021 | -13.82 Mn |
| Sep 30, 2021 | -17.02 Mn |